A phase 1B/2 study of WP1066 in combination with radiation therapy in USA
Latest Information Update: 20 May 2025
At a glance
- Drugs WP 1066 (Primary)
- Indications Brain cancer; Glioblastoma; Glioma
- Focus Adverse reactions
Most Recent Events
- 14 May 2025 According to a Moleculin Biotech media release, company that is actively recruiting at Northwestern University (Northwestern) in this trial. To date Northwestern has recruited 7 subjects. No data has been released.
- 14 May 2025 Status changed to recruiting, according to a Moleculin Biotech media release
- 24 Mar 2023 New trial record